Logo image of GYRE

GYRE THERAPEUTICS INC (GYRE) Stock Fundamental Analysis

NASDAQ:GYRE - Nasdaq - US4037831033 - Common Stock - Currency: USD

9.46  +0.02 (+0.21%)

Premarket: 9.79 +0.33 (+3.49%)

Fundamental Rating

5

GYRE gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. While GYRE has a great health rating, its profitability is only average at the moment. GYRE has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year GYRE was profitable.
GYRE had a negative operating cash flow in the past year.
GYRE had negative earnings in 4 of the past 5 years.
In the past 5 years GYRE reported 4 times negative operating cash flow.
GYRE Yearly Net Income VS EBIT VS OCF VS FCFGYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

With an excellent Return On Assets value of 5.59%, GYRE belongs to the best of the industry, outperforming 93.04% of the companies in the same industry.
With an excellent Return On Equity value of 10.64%, GYRE belongs to the best of the industry, outperforming 94.11% of the companies in the same industry.
The Return On Invested Capital of GYRE (7.26%) is better than 93.75% of its industry peers.
Industry RankSector Rank
ROA 5.59%
ROE 10.64%
ROIC 7.26%
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
GYRE Yearly ROA, ROE, ROICGYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

Looking at the Profit Margin, with a value of 7.20%, GYRE belongs to the top of the industry, outperforming 92.50% of the companies in the same industry.
GYRE has a Operating Margin of 10.36%. This is amongst the best in the industry. GYRE outperforms 93.93% of its industry peers.
Looking at the Gross Margin, with a value of 96.23%, GYRE belongs to the top of the industry, outperforming 95.71% of the companies in the same industry.
Industry RankSector Rank
OM 10.36%
PM (TTM) 7.2%
GM 96.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GYRE Yearly Profit, Operating, Gross MarginsGYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GYRE is destroying value.
GYRE has more shares outstanding than it did 1 year ago.
GYRE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GYRE Yearly Shares OutstandingGYRE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
GYRE Yearly Total Debt VS Total AssetsGYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

GYRE has an Altman-Z score of 9.40. This indicates that GYRE is financially healthy and has little risk of bankruptcy at the moment.
GYRE has a better Altman-Z score (9.40) than 87.68% of its industry peers.
GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.4
ROIC/WACC0.76
WACC9.53%
GYRE Yearly LT Debt VS Equity VS FCFGYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

GYRE has a Current Ratio of 3.60. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
GYRE has a Current ratio of 3.60. This is comparable to the rest of the industry: GYRE outperforms 42.68% of its industry peers.
A Quick Ratio of 3.19 indicates that GYRE has no problem at all paying its short term obligations.
The Quick ratio of GYRE (3.19) is worse than 60.54% of its industry peers.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.19
GYRE Yearly Current Assets VS Current LiabilitesGYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

GYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 103.86%, which is quite impressive.
Looking at the last year, GYRE shows a very negative growth in Revenue. The Revenue has decreased by -28.43% in the last year.
Measured over the past years, GYRE shows a very strong growth in Revenue. The Revenue has been growing by 143.34% on average per year.
EPS 1Y (TTM)103.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.9%
Revenue 1Y (TTM)-28.43%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%-18.82%

3.2 Future

GYRE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 77.26% yearly.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-61.14%
EPS Next 2Y94.64%
EPS Next 3Y77.26%
EPS Next 5YN/A
Revenue Next Year5.07%
Revenue Next 2Y40.6%
Revenue Next 3Y43.57%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GYRE Yearly Revenue VS EstimatesGYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
GYRE Yearly EPS VS EstimatesGYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -500 -1K

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

GYRE is valuated quite expensively with a Price/Earnings ratio of 135.14.
GYRE's Price/Earnings ratio is rather cheap when compared to the industry. GYRE is cheaper than 91.25% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.19, GYRE is valued quite expensively.
A Price/Forward Earnings ratio of 7.93 indicates a rather cheap valuation of GYRE.
Based on the Price/Forward Earnings ratio, GYRE is valued cheaper than 97.32% of the companies in the same industry.
GYRE is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 135.14
Fwd PE 7.93
GYRE Price Earnings VS Forward Price EarningsGYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

91.79% of the companies in the same industry are more expensive than GYRE, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 69.61
GYRE Per share dataGYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

GYRE's earnings are expected to grow with 77.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y94.64%
EPS Next 3Y77.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GYRE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GYRE THERAPEUTICS INC

NASDAQ:GYRE (5/29/2025, 8:00:01 PM)

Premarket: 9.79 +0.33 (+3.49%)

9.46

+0.02 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners1.96%
Inst Owner Change46.06%
Ins Owners6.18%
Ins Owner Change2.09%
Market Cap886.97M
Analysts82.86
Price Target20.4 (115.64%)
Short Float %17.67%
Short Ratio13.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-52.39%
Min EPS beat(2)-102.82%
Max EPS beat(2)-1.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.79%
Min Revenue beat(2)-23.85%
Max Revenue beat(2)16.28%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-80.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-19.65%
Valuation
Industry RankSector Rank
PE 135.14
Fwd PE 7.93
P/S 8.81
P/FCF N/A
P/OCF N/A
P/B 13.02
P/tB 14.07
EV/EBITDA 69.61
EPS(TTM)0.07
EY0.74%
EPS(NY)1.19
Fwd EY12.62%
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS1.07
BVpS0.73
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.59%
ROE 10.64%
ROCE 9.41%
ROIC 7.26%
ROICexc 9.94%
ROICexgc 10.6%
OM 10.36%
PM (TTM) 7.2%
GM 96.23%
FCFM N/A
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 222.77%
Cap/Sales 3.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.19
Altman-Z 9.4
F-Score5
WACC9.53%
ROIC/WACC0.76
Cap/Depr(3y)333.79%
Cap/Depr(5y)313.61%
Cap/Sales(3y)3.51%
Cap/Sales(5y)4.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)103.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-63.9%
EPS Next Y-61.14%
EPS Next 2Y94.64%
EPS Next 3Y77.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-28.43%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%-18.82%
Revenue Next Year5.07%
Revenue Next 2Y40.6%
Revenue Next 3Y43.57%
Revenue Next 5Y-14.87%
EBIT growth 1Y-67.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y61.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.54%
OCF growth 3YN/A
OCF growth 5YN/A